News

AdvanDx, a provider of advanced molecular diagnostic products, has received the FDA 510(k) clearance for E coli/P aeruginosa PNA FISH to identify Escherichia coli or Pseudomonas aeruginosa directly

The financing will be used to mature the company’s product pipeline of antibody therapeutics, particularly within the field of oncology. Kirsten Drejer, CEO of Symphogen, said: “The current

The accurate measurement of human epidermal growth factor type 2 (HER2) gene expression can assist physicians with treatment decisions for patients with cancers in tissues such as breast,

Garnet will use the proceeds to fund Phase II clinical trials of its proprietary human adult bone marrow-derived cells, as well as manufacturing and development. Safeguard Scientifics and

Accrual was completed two months ahead of schedule. The company has also announced that PTC124 has been issued the generic name, ataluren. The pivotal trial is ongoing at

Approval was based on two eight-week studies of more than 800 patients that compared twice-daily doses of Vectical ointment with a vehicle treatment. According to the company, the

As a result, the previous licensing agreement between Warner Chilcott and NexMed related to this product has been terminated. Under the terms of the agreement, NexMed received an

Under terms of the amended agreement, Amylin has committed to advancing the program, resulting in an accelerated $1 million milestone payment to MDRNA. Further, under terms of the

Ablynx and Boehringer Ingelheim have previously entered into an agreement to collaborate on the discovery, development and commercialization of up to 10 different Nanobody therapeutics across a range